All In Biotech

Drug Trial Radar · NCT01208181

A Two-Part, 12-Week Study of Etoricoxib as a Treatment for Rheumatoid Arthritis (RA) (MK-0663-107)

A Phase III, Two-Part, Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial to Assess the Relative Efficacy and Tolerability of Two Doses of MK-0663/Etoricoxib in Patients With Rheumatoid Arthritis

Last checked: Nov 19, 2026Latest source record: Jun 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,404 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,404

Actual

Start

Sep 27, 2010

Primary completion

Jun 9, 2014

Study completion Jul 29, 2014

Sponsor

Lead sponsor
Organon and CoIndustry
Sponsor type
Industry
First posted
Sep 23, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 2-part (6 weeks duration for each part), randomized, double-blind, placebo-controlled study in participants with rheumatoid arthritis. The hypothesis is that etoricoxib (60 mg and 90 mg) administration will demonstrate superior efficacy compared to placebo after 6 weeks of treatment, as measured by the greater mean improvement from baseline in the Disease Activity Score C-Reactive Protein (DAS-28 CRP), and by the greater mean improvement in Patient Global Assessment of Pain (PGAP) from baseline over 6 weeks of treatment. Additionally, the added benefit of increasing the dose of etoricoxib from 60 mg to 90 mg will be assessed in the second part of the study.

Conditions

  • Arthritis, Rheumatoid

Interventions

  • Etoricoxib 60 mgDrug

    One tablet orally once daily for 6 weeks.

  • Etoricoxib 90 mgDrug

    One tablet orally once daily for 6 weeks.

  • Placebo to Etoricoxib 60 mgDrug

    One tablet orally once daily for 6 weeks.

  • Placebo to Etoricoxib 90 mgDrug

    One tablet orally once daily for 6 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time-Weighted Average Change From Baseline in DAS28-CRP in Part 1 (Etoricoxib vs. Placebo)Time frame: Baseline and Week 6
  2. Time-Weighted Average Change From Baseline in Patient Global Assessment of Pain in Part 1 (Etoricoxib vs. Placebo)Time frame: Baseline and Week 6
  3. Percentage of Participants Who Experienced at Least One Adverse Event (AE)Time frame: Up to 112 days
  4. Percentage of Participants Who Discontinued Study Drug Due to an AETime frame: Up to Week 12

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.